Cephalon

BENDEKA

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Cephalon

Bendeka HCPCS:

J9034

HCPCS Code Descriptor:

Injection, bendamustine hcl (bendeka), 1 mg

Category:

J Code

Bendeka NDCs:

63459-0348-04

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Vial

Route of Administration:

Intravenous

Bendeka CPT Codes:

Potential CPT administration codes for Bendeka can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Bendeka:

BENDEKA is an Oncology drug manufactured by Cephalon and administered via the Intravenous route of administration. The J Code: J9034 is aligned to the drug BENDEKA.

BENDEKA is an alkylating drug most often prescribed for use to patients with chronic lymphocytic leukemia or non-Hodgkins lymphoma that has progressed while being treated with rituximab. It’s a mechlorethamine derivative that forms alkyl groups that covalently bond with electron-rich nucleophilic structures like DNA, causing DNA crosslinks that can lead to cell death via various pathways. BENDEKA (J9034) is most often used to treat adult patients. It is contraindicated for pregnant women and patients with renal or hepatic insufficiency. Patient assistance can be found through the Teva Cares Foundation.

ACCESS PRICING AND MORE BY REGISTERING

J9034 Added Date:

January 1, 2017

J9034 Effective Date:

January 1, 2017

J9034 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Bendeka billing and coding information.
Bendeka patient assistance information can be found through Teva Cares at the URL: http://www.tevacares.org/
BENDEKA prescribing information can be found at the link below:
Information regarding BENDEKA’s side effects can be found at MedlinePlus